Shanghai Longwood Biopharmaceuticals Co., Ltd.
Quick facts
Phase 3 pipeline
- LW402 · Diabetes
LW402 is a small molecule that targets the SGLT2 receptor.
Phase 2 pipeline
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Shanghai Longwood Biopharmaceuticals Co., Ltd. portfolio CI brief
- Shanghai Longwood Biopharmaceuticals Co., Ltd. pipeline updates RSS
Frequently asked questions about Shanghai Longwood Biopharmaceuticals Co., Ltd.
What is Shanghai Longwood Biopharmaceuticals Co., Ltd.'s pipeline?
Shanghai Longwood Biopharmaceuticals Co., Ltd. has 1 drugs in Phase 3, 1 in Phase 2, 2 in Phase 1. Late-stage candidates include LW402.
Related
- Sector hub: All tracked pharma companies